XDG3:XETRA:XETRA-Xtrackers MSCI Global SDG 3 Good Health UCITS ETF 1C USD EUR (EUR)

ETF | Others |

Last Closing

USD 33.2

Change

-0.12 (-0.35)%

Market Cap

USD 0.14B

Volume

19.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.14 (+0.26%)

USD 426.26B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.05 (+0.32%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.07 (+0.24%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.10 (+0.35%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.11 (+0.43%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.56 (+1.22%)

USD 104.42B
8R80:XETRA Amundi Index Solutions - Amund..

+0.06 (+0.04%)

USD 104.42B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.16 (+0.32%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.73 (+0.72%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+6.48 (+1.11%)

USD 80.38B

ETFs Containing XDG3:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.86% 80% B- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.86% 80% B- 78% C+
Trailing 12 Months  
Capital Gain 17.03% 68% D+ 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.03% 67% D+ 67% D+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.69% 43% F 43% F
Dividend Return 2.69% 42% F 41% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5.93% 79% B- 83% B
Risk Adjusted Return 45.28% 51% F 55% F
Market Capitalization 0.14B 39% F 35% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.